UBS Group’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $164K | Sell |
41,042
-11,936
| -23% | -$47.7K | ﹤0.01% | 5603 |
|
|
2025
Q1 | $48.2K | Buy |
52,978
+16,803
| +46% | +$15.3K | ﹤0.01% | 6337 |
|
|
2024
Q4 | $100K | Buy |
36,175
+10,411
| +40% | +$28.8K | ﹤0.01% | 5658 |
|
|
2024
Q3 | $135K | Buy |
25,764
+9,991
| +63% | +$52.3K | ﹤0.01% | 4968 |
|
|
2024
Q2 | $70.3K | Sell |
15,773
-32,187
| -67% | -$144K | ﹤0.01% | 5281 |
|
|
2024
Q1 | $367K | Buy |
47,960
+1,753
| +4% | +$13.4K | ﹤0.01% | 4312 |
|
|
2023
Q4 | $197K | Buy |
46,207
+27,290
| +144% | +$116K | ﹤0.01% | 4609 |
|
|
2023
Q3 | $79.5K | Sell |
18,917
-2,660
| -12% | -$11.2K | ﹤0.01% | 4865 |
|
|
2023
Q2 | $120K | Buy |
+21,577
| New | +$120K | ﹤0.01% | 4814 |
|
|
2023
Q1 | – | Sell |
-2,834
| Closed | -$2.98K | – | 8720 |
|
|
2022
Q4 | $2.98K | Buy |
+2,834
| New | +$2.98K | ﹤0.01% | 8391 |
|
|
2022
Q3 | – | Sell |
-115
| Closed | -$1K | – | 9433 |
|
|
2022
Q2 | $1K | Sell |
115
-6,198
| -98% | -$53.9K | ﹤0.01% | 8842 |
|
|
2022
Q1 | $26K | Sell |
6,313
-915
| -13% | -$3.77K | ﹤0.01% | 6107 |
|
|
2021
Q4 | $49K | Buy |
+7,228
| New | +$49K | ﹤0.01% | 5813 |
|
|
2021
Q3 | – | Sell |
-48
| Closed | -$1K | – | 8555 |
|
|
2021
Q2 | $1K | Sell |
48
-954
| -95% | -$19.9K | ﹤0.01% | 8040 |
|
|
2021
Q1 | $20K | Buy |
+1,002
| New | +$20K | ﹤0.01% | 6363 |
|
|
2020
Q4 | – | Sell |
-536
| Closed | -$14K | – | 7476 |
|
|
2020
Q3 | $14K | Buy |
+536
| New | +$14K | ﹤0.01% | 5709 |
|